Sun Pharmaceutical Industries Ltd announced shareholder approval for its Organon & Co acquisition. This significant milestone moves the proposed transaction closer to completion. Organon is expected to become a wholly owned subsidiary of Sun Pharma's US arm. The all-cash deal values Organon at an enterprise valuation of USD 11.75 billion. Regulatory approvals remain a key condition for the finalization of this merger.